CLINICAL RESEARCH: ATHEROSCLEROSIS
The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis
Yoav Michowitz, MD*,
Emil Goldstein, MD*,
Arie Roth, MD*,
Arnon Afek, MD*,
Anastasia Abashidze, BSc*,
Yanai Ben Gal, MD ,
Gad Keren, MD, FACC* and
Jacob George, MD*,*
* Department of Cardiology, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Department of Cardiothoracic Surgery, Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Manuscript received October 15, 2004;
revised manuscript received November 26, 2004,
accepted December 6, 2004.
* Reprint requests and correspondence: Dr. Jacob George, Department of Cardiology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (Email: jacobg{at}post.tau.ac.il).
OBJECTIVES: Herein, we determined the significance of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in atherosclerotic vascular disease.
BACKGROUND: Inflammation is associated with the pathogenesis of atherosclerosis. The TNF-related apoptosis-inducing ligand/APO-2L, a member of the TNF superfamily, has a role in apoptosis induction and is recognized for its immunomodulatory properties.
METHODS: Stable and vulnerable atherosclerotic human plaques and aortas from atherosclerotic mice were assayed for the presence of TRAIL, and its inducibility was assayed by immunoblot and real-time polymerase chain reaction on peripheral mononuclear cells incubated with oxidized low-density lipoprotein (oxLDL). Enzyme-linked immunosorbent assay was used for the determination of soluble TRAIL levels in atherosclerotic patients.
RESULTS: Tumor necrosis factor-related apoptosis-inducing ligand is present in stable atherosclerotic lesions, is increased in vulnerable plaques, and is found to colocalize with CD3 cells and oxLDL. The TNF-related apoptosis-inducing ligand messenger ribonucleic acid (mRNA) and protein expression was up-regulated in peripheral blood mononuclear cells after incubation with oxLDL. Serum levels of soluble TRAIL but not TNF-alpha or Fas-ligand were reduced significantly in patients with unstable angina as compared with patients with stable atherosclerotic disease and healthy subjects. A negative correlation was demonstrated between soluble TRAIL and C-reactive protein levels but not with levels of mRNA of TRAIL in peripheral blood mononuclear cells.
CONCLUSIONS: Tumor necrosis factor-related apoptosis-inducing ligand is expressed in plaque-infiltrating CD3 cells and induced by oxLDL, whereas levels of soluble TRAIL are reduced in patients with acute coronary syndromes and negatively correlate with C-reactive protein levels. These results support a possible role for TRAIL in atherosclerosis.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CRP = C-reactive protein | | hsCRP = high-sensitivity C-reactive protein | | LPC = lysophosphatidylcholine | | oxLDL = oxidized low-density lipoprotein | | mRNA = messenger ribonucleic acid | | NCA = normal coronary arteries | | PBMCs = peripheral blood mononuclear cells | | RT-PCR = reverse-transcription polymerase chain reaction | | TNF = tumor necrosis factor | | TRAIL = tumor necrosis factor-related apoptosis-inducing ligand |
|
This article has been cited by other articles:
|
|
|
|
 
J. F. Lula, M. O. d. C. Rocha, M. d. C. P. Nunes, A. L. P. Ribeiro, M. M. Teixeira, M. T. Bahia, and A. Talvani
Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction
Eur J Heart Fail,
September 1, 2009;
11(9):
825 - 831.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Simoncini, M.-S. Njock, S. Robert, L. Camoin-Jau, J. Sampol, J.-R. Harle, C. Nguyen, F. Dignat-George, and F. Anfosso
TRAIL/Apo2L Mediates the Release of Procoagulant Endothelial Microparticles Induced by Thrombin In Vitro: A Potential Mechanism Linking Inflammation and Coagulation
Circ. Res.,
April 24, 2009;
104(8):
943 - 951.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Niessner, P. J. Hohensinner, K. Rychli, S. Neuhold, G. Zorn, B. Richter, M. Hulsmann, R. Berger, D. Mortl, K. Huber, et al.
Prognostic value of apoptosis markers in advanced heart failure patients
Eur. Heart J.,
April 1, 2009;
30(7):
789 - 796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Kavurma, N. Y. Tan, and M. R. Bennett
Death Receptors and Their Ligands in Atherosclerosis
Arterioscler Thromb Vasc Biol,
October 1, 2008;
28(10):
1694 - 1702.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. M. Kavurma, M. Schoppet, Y. V. Bobryshev, L. M. Khachigian, and M. R. Bennett
TRAIL Stimulates Proliferation of Vascular Smooth Muscle Cells via Activation of NF-{kappa}B and Induction of Insulin-like Growth Factor-1 Receptor
J. Biol. Chem.,
March 21, 2008;
283(12):
7754 - 7762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Morony, Y. Tintut, Z. Zhang, R. C. Cattley, G. Van, D. Dwyer, M. Stolina, P. J. Kostenuik, and L. L. Demer
Osteoprotegerin Inhibits Vascular Calcification Without Affecting Atherosclerosis in ldlr( / ) Mice
Circulation,
January 22, 2008;
117(3):
411 - 420.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. M. Blanco-Colio, J. L. Martin-Ventura, B. Munoz-Garcia, J. Orbe, J. A. Paramo, J.-B. Michel, A. Ortiz, O. Meilhac, and J. Egido
Identification of Soluble Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of Subclinical Atherosclerosis
Arterioscler Thromb Vasc Biol,
April 1, 2007;
27(4):
916 - 922.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Niessner, K. Sato, E. L. Chaikof, I. Colmegna, J. J. Goronzy, and C. M. Weyand
Pathogen-Sensing Plasmacytoid Dendritic Cells Stimulate Cytotoxic T-Cell Function in the Atherosclerotic Plaque Through Interferon-{alpha}
Circulation,
December 5, 2006;
114(23):
2482 - 2489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Waxman, F. Ishibashi, and J. E. Muller
Detection and Treatment of Vulnerable Plaques and Vulnerable Patients: Novel Approaches to Prevention of Coronary Events
Circulation,
November 28, 2006;
114(22):
2390 - 2411.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-K. L. Robertson and G. K Hansson
T Cells in Atherogenesis: For Better or For Worse?
Arterioscler Thromb Vasc Biol,
November 1, 2006;
26(11):
2421 - 2432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Secchiero, R. Candido, F. Corallini, S. Zacchigna, B. Toffoli, E. Rimondi, B. Fabris, M. Giacca, and G. Zauli
Systemic Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Delivery Shows Antiatherosclerotic Activity in Apolipoprotein E-Null Diabetic Mice
Circulation,
October 3, 2006;
114(14):
1522 - 1530.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Hofbauer, M. Schoppet, M. Christ, J. Teichmann, and U. Lange
Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis
Rheumatology,
October 1, 2006;
45(10):
1218 - 1222.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Y. Shin, Y. G. Shin, and C. H. Chung
Elevated Serum Osteoprotegerin Levels Are Associated With Vascular Endothelial Dysfunction in Type 2 Diabetes
Diabetes Care,
July 1, 2006;
29(7):
1664 - 1666.
[Full Text]
[PDF]
|
|
|
|
